• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study.

作者信息

Aoki Kazunari, Ishikawa Takayuki, Ishiyama Ken, Aoki Jun, Itonaga Hidehiro, Fukuda Takahiro, Kakihana Kazuhiko, Uchida Naoyuki, Ueda Yasunori, Eto Tetsuya, Mori Takehiko, Kondo Tadakazu, Iwato Koji, Morishima Yasuo, Tanaka Junji, Atsuta Yoshiko, Miyazaki Yasushi

机构信息

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.

出版信息

Br J Haematol. 2015 Feb;168(3):463-6. doi: 10.1111/bjh.13124. Epub 2014 Sep 17.

DOI:10.1111/bjh.13124
PMID:25228239
Abstract
摘要

相似文献

1
Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study.老年晚期骨髓增生异常综合征患者减低剂量预处理的异基因造血细胞移植：一项全国性研究。
Br J Haematol. 2015 Feb;168(3):463-6. doi: 10.1111/bjh.13124. Epub 2014 Sep 17.
2
Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.异基因干细胞移植治疗成人骨髓增生异常综合征：移植前疾病负担的重要性。
Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.
3
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.低强度预处理用于骨髓增生异常综合征和急性髓系白血病的异基因造血干细胞移植
Curr Opin Oncol. 2007 Nov;19(6):660-6. doi: 10.1097/CCO.0b013e3282f0e188.
4
Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.40-60 岁 AML/骨髓增生异常综合征患者行异基因移植时，预处理强度的影响。
Bone Marrow Transplant. 2011 Apr;46(4):516-22. doi: 10.1038/bmt.2010.164. Epub 2010 Jul 12.
5
Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.氟达拉滨和马法兰用于异基因造血干细胞移植的减低强度预处理与骨髓增生异常综合征的持久疾病控制相关。
Bone Marrow Transplant. 2007 Nov;40(9):843-50. doi: 10.1038/sj.bmt.1705801. Epub 2007 Aug 27.
6
Transplants in myelodysplastic syndromes.骨髓增生异常综合征中的移植
Hematol Oncol Clin North Am. 2014 Dec;28(6):1011-22. doi: 10.1016/j.hoc.2014.08.012. Epub 2014 Sep 29.
7
Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.观点：在减低强度预处理时代，异基因造血细胞移植的作用是什么——是否仍然存在年龄上限？聚焦于髓系肿瘤。
Leukemia. 2007 Jul;21(7):1357-62. doi: 10.1038/sj.leu.2404741. Epub 2007 May 17.
8
Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.移植前血清铁蛋白对接受低强度预处理异基因造血干细胞移植的骨髓增生异常综合征或继发性急性髓系白血病患者结局的影响。
Leuk Res. 2010 Jun;34(6):723-7. doi: 10.1016/j.leukres.2009.10.028. Epub 2009 Nov 26.
9
Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?哪些骨髓增生异常综合征患者应接受异基因干细胞移植，以及我们应该何时进行移植？
Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S43-9. doi: 10.1016/j.clml.2015.04.002.
10
Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older.异基因造血细胞移植对70岁及以上骨髓增生异常综合征患者是一种安全有效的治疗方法。
Biol Blood Marrow Transplant. 2017 Jan;23(1):1-2. doi: 10.1016/j.bbmt.2016.11.013. Epub 2016 Nov 16.

引用本文的文献

1
Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy.低原始细胞 MDS 患者异基因移植后预处理强度对预后的影响：日本移植与细胞治疗学会成人 MDS 工作组的全国性回顾性研究。
Bone Marrow Transplant. 2024 Aug;59(8):1107-1117. doi: 10.1038/s41409-024-02297-0. Epub 2024 May 7.
2
Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database.异基因骨髓移植与 HLA 完全相合的亲属外周血造血干细胞移植治疗骨髓增生异常综合征和少部分急性髓系白血病患者：全国数据库的倾向性评分分析。
Ann Hematol. 2023 May;102(5):1215-1227. doi: 10.1007/s00277-023-05167-9. Epub 2023 Mar 15.
3
Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.50岁以上患者异基因造血干细胞移植治疗骨髓增生异常综合征和急性髓系白血病的减低强度预处理：一项系统评价和荟萃分析
J Cancer Res Clin Oncol. 2017 Sep;143(9):1853-1864. doi: 10.1007/s00432-017-2429-z. Epub 2017 May 3.
4
[Advances in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes].[异基因造血干细胞移植治疗骨髓增生异常综合征的进展]
Zhonghua Xue Ye Xue Za Zhi. 2016 May 14;37(5):432-6. doi: 10.3760/cma.j.issn.0253-2727.2016.05.019.